Nā API peptide
-
NMN
Hōʻike nā haʻawina preclinical a me nā kānaka mua i ka NMN e hoʻoikaika i ka lōʻihi o ke ola, ka hoʻomanawanui kino, a me ka hana naʻau.
Nā hiʻohiʻona API:
Maʻemaʻe kiʻekiʻe ≥99%
ʻO ka lāʻau lapaʻau, kūpono no ka waha a i ʻole ka injectable formulations
Hana ʻia ma lalo o nā kūlana GMP-like
He kūpono ka NMN API no ka hoʻohana ʻana i nā mea hoʻohui anti-aging, metabolic therapy, a me ka noiʻi lōʻihi.
-
Glucagon
ʻO Glucagon kahi hormone peptide kūlohelohe i hoʻohana ʻia ma ke ʻano he lāʻau ulia pōpilikia no ka hypoglycemia koʻikoʻi a aʻo ʻia no kāna kuleana i ka hoʻoponopono metabolic, pohō kaumaha, a me nā diagnostics digestive.
-
Motixafortide
ʻO Motixafortide kahi peptide antagonist synthetic CXCR4 i hoʻomohala ʻia e hoʻoneʻe i nā cell hematopoietic stem (HSCs) no ka hoʻololi autologous a ke aʻo ʻia nei hoʻi i ka oncology a me ka immunotherapy.
-
ʻO Glepaglutide
ʻO Glepaglutide kahi analog GLP-2 lōʻihi i hoʻomohala ʻia no ka mālama ʻana i ka maʻi pōkole pōkole (SBS). Hoʻonui ia i ka absorption intestinal a me ka ulu ʻana, kōkua i nā mea maʻi e hōʻemi i ka hilinaʻi ʻana i ka meaʻai makua.
-
Elamipretide
ʻO ka Elamipretide kahi tetrapeptide i manaʻo ʻia i ka mitochondria i hoʻomohala ʻia e mālama i nā maʻi i hoʻokumu ʻia e ka mitochondrial dysfunction, me ka myopathy mitochondrial mua, Barth syndrome, a me ka pau ʻole o ka naʻau.
-
Pegcetacoplan
ʻO Pegcetacoplan kahi peptide cyclic pegylated e hana ana ma ke ʻano he C3 complement inhibitor, i hoʻomohala ʻia no ka mālama ʻana i nā maʻi complement-mediated e like me ka paroxysmal nocturnal hemoglobinuria (PNH) a me ka geographic atrophy (GA) i ka macular degeneration pili makahiki.
-
Palopegteriparatide
ʻO ka Palopegteriparatide kahi agonist hormone receptor agonist lōʻihi (PTH1R agonist), i hoʻomohala ʻia no ka mālama ʻana i ka hypoparathyroidism mau loa. He analog pegylated o PTH (1-34) i hoʻolālā ʻia e hāʻawi i ka hoʻoponopono calcium hoʻomau me ka hoʻopaʻa ʻana i hoʻokahi pule.
-
GHRP-6
ʻO GHRP-6 (Growth Hormone Releasing Peptide-6) he hexapeptide synthetic e hana ana ma ke ʻano he secretagogue hormone ulu, e hoʻoulu ana i ka hoʻokuʻu maoli ʻana o ke kino o ka hormone ulu (GH) ma ka hoʻoulu ʻana i ka GHSR-1a receptor.
Nā hiʻohiʻona API:
Maʻemaʻe ≥99%
Hana ʻia ma o ka solid-phase peptide synthesis (SPPS)
Hāʻawi ʻia no ka R&D a me ka hoʻohana ʻana i ka ʻoihana
ʻO GHRP-6 kahi peptide noiʻi maʻamau no ke kākoʻo metabolic, hoʻoulu hou ʻana i ka ʻiʻo, a me ka modulation hormonal.
-
GHRP-2
ʻO GHRP-2 (Growth Hormone Releasing Peptide-2) he hexapeptide synthetic a me ka potent growth hormone secretagogue, i hoʻolālā ʻia e hoʻoulu i ka hoʻokuʻu kūlohelohe o ka hormone ulu (GH) ma o ka hoʻoulu ʻana i ka GHSR-1a receptor i ka hypothalamus a me ka pituitary.
Nā hiʻohiʻona API:
Maʻemaʻe ≥99%
Loaʻa no ka R&D a me ka lako kalepa, me ka palapala QC piha
ʻO GHRP-2 kahi peptide noiʻi koʻikoʻi ma nā kahua o ka endocrinology, lāʻau lapaʻau hou, a me nā lāʻau lapaʻau pili makahiki.
-
Hexarelin
ʻO Hexarelin kahi synthetic growth hormone secretagogue peptide (GHS) a me ka potent GHSR-1a agonist, i hoʻomohala ʻia e hoʻoulu i ka hoʻokuʻu ʻana o ka hormone ulu (GH). No ka ʻohana mimetic ghrelin a ua haku ʻia me ʻeono amino acids (hexapeptide), e hāʻawi ana i ka hoʻomaikaʻi ʻana i ka metabolic stability a me nā hopena hoʻokuʻu GH ikaika i hoʻohālikelike ʻia me nā analogs mua e like me GHRP-6.
Nā hiʻohiʻona API:
Maʻemaʻe ≥ 99%
Hana ʻia ma o ka solid-phase peptide synthesis (SPPS)
Nā kūlana like GMP, endotoxin haʻahaʻa a me nā koena solvent
Hāʻawi maʻalahi: R&D i ka pālākiō kalepa
-
Melanotana II
Nā hiʻohiʻona API:
Maʻemaʻe kiʻekiʻe ≥ 99%
Hoʻopili ʻia ma o ka solid-phase peptide synthesis (SPPS)
Haʻahaʻa endotoxin, haʻahaʻa koena solvents
Loaʻa ma R&D i ka pālākiō pāʻoihana -
Melanotana 1
Hana ʻia ʻo Melanotan 1 API me ka hoʻohana ʻana i ka ʻenehana solid phase peptide synthesis (SPPS) ma lalo o nā kūlana mana maikaʻi e like me GMP.
-
Maʻemaʻe kiʻekiʻe ≥99%
-
ʻO ka hoʻohuihui peptide-phase paʻa (SPPS)
-
Nā kūlana hana like GMP
-
Nā palapala piha: COA, MSDS, ʻikepili paʻa
-
Hiki ke hoʻolako ʻia: R&D i nā pae pāʻoihana
-